Repurposing antipsychotic drugs for cancer treatment: current evidence and future perspectives

Georgios D. Lianos,George A. Alexiou,Stefano Rausei,Vasiliki Galani,Michail Mitsis,Athanasios P. Kyritsis
DOI: https://doi.org/10.1080/14737140.2022.1987221
2021-10-15
Expert Review of Anticancer Therapy
Abstract:Today cancer is, undoubtedly, a major health concern. Cancer research is now at a critical crossroad. New data and fresh concepts are transforming traditional views on biology, tumorigenesis, and therapeutic interventions. Current evidence suggests that in the next ten years approximately 22 million new cancer cases and 13 million cancer-related deaths are expected worldwide. Traditional and new chemotherapy regimens include several agents [1,2]. Unfortunately, a significant increase in survival rates of cancer patients represents a distant scientific target. The regimens for cancer patients has remained dramatically unchanged for many years and recent evidence suggests that the development of novel anticancer drugs remains a challenging concept [2]. Unfortunately, de novo anticancer drug discovery and development has a low success rate and FDA approves a very small number of novel anticancer drugs every year [2–4]. Today, there is increased scientific interest for drug repurposing which could provide affordable treatments to patients as soon as possible [3]. The cost of developing new drugs is enormous and the process is time consuming. When an agent has a known pharmacokinetic, pharmacodynamic, and safety profile then the agent can progress directly in phases II/III. Thus, drug repurposing may bypass several processes and is associated with lower cost [4].
oncology
What problem does this paper attempt to address?